The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Popova E.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Briukhov V.V.

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Krotenkova M.V.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Primary-progressive multiple sclerosis as an atypical demyelinating process

Authors:

Popova E.V., Briukhov V.V., Boĭko A.N., Krotenkova M.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(10‑2): 42‑46

DOI: 10.17116/jnevro201611610242-46

Read: 7704 times

Download PDF (RU)
Contact the author
Table of contents

PRIMARY-PROGRESSIVE MULTIPLE SCLEROSIS AS AN ATYPICAL DEMYELINATING PROCESS
PRIMARY-PROGRESSIVE MULTIPLE SCLEROSIS AS AN ATYPICAL DEMYELINATING PROCESS

To cite this article:

Popova EV, Briukhov VV, Boĭko AN, Krotenkova MV. Primary-progressive multiple sclerosis as an atypical demyelinating process. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(10‑2):42‑46. (In Russ.)
https://doi.org/10.17116/jnevro201611610242-46

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

This article presents an overview of current data on primary-progressive multiple sclerosis (MS). In this aspect, the authors consider its characteristics in comparison to other MS forms as well as possible markers of the disease, criteria of diagnosis and therapeutic options in the present and the future times.

Keywords:

primary-progressive multiple sclerosis
pathogenesis of multiple sclerosis

Authors:

Popova E.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Briukhov V.V.

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Krotenkova M.V.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Close metadata

References:

  1. Lublin F, Reingold S. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology. 1996;46(4):907-911. doi: 10.1212/wnl.46.4.907
  2. Montalban X. Primary progressive multiple sclerosis. Current Opinion in Neurology. 2005;18(3):261-266. doi: 10.1097/01.wco.0000169742.37159.e9
  3. Ebers G. Natural history of primary progressive multiple sclerosis. Multiple Sclerosis. 2004;10(1 suppl):8-15. doi: 10.1177/135245850401000103
  4. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology. 2005;65(12):1919-1923. doi: 10.1212/01.wnl.0000188880.17038.1d
  5. Confavreux C, Vukusic S. Reply to: Age at disability milestones in multiple sclerosis and history of multiple sclerosis: a unifying concept. Brain. 2006;129(12):57-57. doi: 10.1093/brain/awl313
  6. Olerup O, Hillert J, Fredrikson S et al. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proceedings of the National Academy of Sciences. 1989;86(18):7113-7117. doi: 10.1073/pnas.86.18.7113
  7. McDonnell G, Mawhinney H, Graham C, Hawkins S, Middleton D. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. Journal of the Neurological Sciences. 1999;165(1):77-83. doi: 10.1016/s0022-510x(99)00084-2
  8. Greer J. The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRV 1 chain is associated with the clinical course of multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. 2005;76(5):656-662. doi: 10.1136/jnnp.2004.042168
  9. Booth D, Arthur A, Teutsch S et al. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis. Journal of Molecular Medicine. 2005;83(10):822-830. doi: 10.1007/s00109-005-0684-y
  10. Kremenchutzky M. The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease. Brain. 2006;129(3):584-594. doi: 10.1093/brain/awh721
  11. Revesz T, Kidd D, Thompson A, Barnard R, McDonald W. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 1994;117(4):759-765. doi: 10.1093/brain/117.4.759
  12. Lucchinetti C. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: A study of 113 cases. Brain. 1999;122(12):2279-2295. doi: 10.1093/brain/122.12.2279
  13. Lucchinetti C, BrpїЅck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Annals of Neurology. 2000;47(6):707-717. doi: 10.1002/1531-8249(200006)47:6707::aid-ana33.0.co;2-q
  14. Bitsch A. Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation. Brain. 2000;123(6):1174-1183. doi: 10.1093/brain/123.6.1174
  15. Kutzelnigg A. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128(11):2705-2712. doi: 10.1093/brain/awh641
  16. Brettschneider J, Maier M, Arda S et al. Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis. Multiple Sclerosis. 2005;11(3):261-265. doi: 10.1191/1352458505ms1159oa
  17. Pender M. The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair? Journal of Clinical Neuroscience. 2004;11(7):689-692. doi: 10.1016/j.jocn.2003.12.013
  18. Leech S, Kirk J, Plumb J, McQuaid S. Persistent endothelial abnormalities and blood?brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol. 2007;33(1). doi: 10.1111/j.1365-2990.2006.00781.x
  19. Filippi M, Rocca M, Ciccarelli O et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. The Lancet Neurology. 2016;15(3):292-303. doi: 10.1016/s1474-4422(15)00393-2
  20. Montalban X, Sastre-Garriga J, Filippi M et al. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. Multiple Sclerosis. 2009;15(12):1459-1465. doi: 10.1177/1352458509348422
  21. Polman C, Reingold S, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology. 2011;69(2):292-302. doi: 10.1002/ana.22366
  22. Kelly S, Kinsella K, Duggan M, Tubridy N, McGuigan C, Hutchinson M. A proposed modification to the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis. Multiple Sclerosis Journal. 2012;19(8):1095-1100. doi: 10.1177/1352458512464829
  23. Miller D, Leary S. Primary-progressive multiple sclerosis. The Lancet Neurology. 2007;6(10):903-912. doi: 10.1016/s1474-4422(07)70243-0
  24. Antel J, Antel S, Caramanos Z, Arnold D, Kuhlmann T. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathologica. 2012;123(5):627-638. doi: 10.1007/s00401-012-0953-0
  25. Leray E, Yaouanq J, Le Page E et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133(7):1900-1913. doi: 10.1093/brain/awq076
  26. Leary S, Miller D, Stevenson V, Brex P, Chard D, Thompson A. Interferon V-1a in primary progressive MS: An exploratory, randomized, controlled trial. Neurology. 2003;60(1):44-51. doi: 10.1212/wnl.60.1.44
  27. Montalban X, Sastre-Garriga J, Tintore M et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Multiple Sclerosis. 2009;15(10):1195-1205. doi: 10.1177/1352458509106937
  28. Wolinsky J, Narayana P, O’Connor P et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Annals of Neurology. 2007;61(1):14-24. doi: 10.1002/ana.21079
  29. Lublin F, Miller D, Freedman M et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. 2016;387(10023):1075-1084. doi: 10.1016/s0140-6736(15)01314-8
  30. Hawker K, O’Connor P, Freedman M et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology. 2009;66(4):460-471. doi: 10.1002/ana.21867
  31. Susman E. News from the ECTRIMS Annual Meeting. Neurology Today. 2015;15(21):10-11. doi: 10.1097/01.nt.0000473697.22402.44
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.